Inhibikase Therapeutics Receives Grant from U.S. National Institutes of Health to Evaluate IkT-148009 for the Treatment of Multiple System Atrophy
- Thursday, September 23, 2021, 7:10
- Environment
- Add a comment
ATLANTA, Sept. 23, 2021 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson’s disease and related disorders, today announced that the Company has been…
About the Author
adminasapcorp has written 41785 stories on this site.